Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Regenerative medicine industry 360º synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Type trends
2.1.4 Application trends
Chapter 3 Regenerative Medicine Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of chronic diseases worldwide
3.2.1.2 Rising investment in development of innovative medicines
3.2.1.3 High adoption of stem cell technology in disease treatment
3.2.1.4 Strong product pipeline of potential therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory framework
3.2.2.2 High cost associated with some regenerative medicine therapy
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By application
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Regenerative Medicine Market Estimates and Forecast, By Type, 2018-2032 (USD Million)
5.1 Key trends, by type
5.2 Cell therapy
5.3 Tissue engineering
5.4 Gene therapy
5.5 Other types
Chapter 6 Regenerative Medicine Market Estimates and Forecast, By Application, 2018-2032 (USD Million)
6.1 Key trends, by application
6.2 Oncology
6.3 Musculoskeletal
6.4 Neurology
6.5 Cardiovascular
6.6 Wound healing
6.7 Ophthalmology
6.8 Other applications
Chapter 7 Regenerative Medicine Market Estimates and Forecast, By Region, 2018-2032 (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Sweden
7.3.7 The Netherlands
7.3.8 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 Middle East & Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Rest of Middle East & Africa
Chapter 8 Company Profiles
8.1 Novartis AG
8.2 Amgen Inc.
8.3 Bristol Myers Squibb
8.4 BLUEBIRD BIO
8.5 GC Pharma
8.6 GlaxoSmithKline plc
8.7 ANTEROGEN
8.8 BIOSOLUTIONS
8.9 TERUMO BCT
8.10 AVITA MEDICAL
8.11 Smith and Nephew
8.12 ORGANOGENESIS
